Loading...
HCM logo

HUTCHMED (China) LimitedNasdaqGS:HCM Stock Report

Market Cap US$1.9b
Share Price
US$10.85
US$22.78
52.4% undervalued intrinsic discount
1Y-32.0%
7D-4.8%
1D
Portfolio Value
​
View

HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$1.9b

HUTCHMED (China) (HCM) Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. More details

HCM fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance5/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 65.8% below our estimate of its fair value

Revenue is forecast to grow 13.55% per year

Earnings grew by 1111% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 67% per year for the next 3 years

Large one-off items impacting financial results


HCM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£10.85
52 Week HighUK£19.50
52 Week LowUK£10.71
Beta0.37
1 Month Change-17.36%
3 Month Change-21.89%
1 Year Change-32.02%
3 Year Change-7.97%
5 Year Change-63.86%
Change since IPO-19.63%

Recent News & Updates

Recent updates

Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. Warm autoimmune hemolytic anemia is an autoimmune disorder characterized by premature destruction of healthy red blood cells (hemolysis). The main goal of the phase 2 stage is evaluating the safety and preliminary efficacy of sovleplenib and main goal is the proportion of patients with overall hemoglobin (Hb) response by week 24. If results are positive, phase 3 stage will be started wherein the main goal would be the proportion of patients who achieve a durable Hb response by week 24, the company said in an Oct. 10 press release. The company expects to enroll 110 patients. Hutchmed noted that it currently retains all rights to sovleplenib worldwide. The drug is also being studied in immune thrombocytopenia, indolent non-Hodgkin's lymphoma and multiple subtypes of B-cell malignancies in China, U.S. and Europe.
Seeking Alpha • Aug 09

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Hutchmed (China) (NASDAQ:HCM) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004. Inmagene is developing IMG-004 to potentially treat immunological diseases. The study aims to evaluate IMG-004's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy people. Inmagene's Chairman and CEO Jonathan Wang said that  IMG-004 was the second drug candidate under the collaboration with Hutchmed which the company successfully advanced into clinical studies this year. "Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022," Wang noted.
Seeking Alpha • Aug 01

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2 bridging study of tazemetostat in China to treat patients with relapsed/refractory follicular lymphoma (R/R FL). Tazemetostat is developed by Epizyme (NASDAQ:EPZM) and Hutchmed has an agreement with the Cambridge, Mass.-based company to develop and sell the drug in China, Hong Kong, Macau and Taiwan. Epizyme is in the process of being acquired by France's Ipsen. Hutchmed said that the main goal of the study is to evaluate the efficacy of tazemetostat to treat patients with R/R FL who have mutations in the EZH2 gene (Cohort 1). Meanwhile, the secondary goals is to check efficacy of the drug in treating patients with R/R FL who have EZH2 wild-type (Cohort 2) and to evaluate safety. Follicular lymphoma occurs when the body develops abnormal B lymphocytes, type of white blood cells.
Seeking Alpha • Jul 15

Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83

Hutchmed (China) (NASDAQ:HCM) said it began a phase 1 trial of HMPL-A83 in patients with advanced malignant neoplasms in China. The first patient received their first dose on July 15. The phase 1 study will evaluate the safety and preliminary efficacy of HMPL-A83 in patients with advanced malignant neoplasms and also find a phase 2 dose and maximum tolerated dose. Malignant neoplasms are cancerous tumors that can also spread to other parts of the body.
Seeking Alpha • Jul 06

Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema

Inmagene Biopharmaceuticals and Hutchmed (China) (​HCM) said the first person, based in Australia, was dosed in a global phase 1 trial of IMG-007 to treat  adult patients with moderate to severe atopic dermatitis (eczema). The early-stage trial is a dose-escalation study in healthy volunteers, and a dose-escalation, multiple-dose study in adult patients with moderate to severe atopic dermatitis.

Shareholder Returns

HCMUS PharmaceuticalsUS Market
7D-4.8%3.7%-2.7%
1Y-32.0%40.0%22.5%

Return vs Industry: HCM underperformed the US Pharmaceuticals industry which returned 40% over the past year.

Return vs Market: HCM underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: HCM has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: HCM's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,796Johnny Chengwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM fundamental statistics
Market capUS$1.89b
Earnings (TTM)US$456.91m
Revenue (TTM)US$548.51m
4.1x
P/E Ratio
3.4x
P/S Ratio

Is HCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM income statement (TTM)
RevenueUS$548.51m
Cost of RevenueUS$484.64m
Gross ProfitUS$63.87m
Other Expenses-US$393.04m
EarningsUS$456.91m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.53
Gross Margin11.64%
Net Profit Margin83.30%
Debt/Equity Ratio7.4%

How did HCM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 17:27
End of Day Share Price 2026/06/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 53 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish